Cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment in endocrine therapy resistant ER plus breast cancer

被引：0
作者：
Griffiths, Jason I.
Cosgrove, Patrick A.
Castaneda, Eric Medina
Nath, Aritro
Chen, Jinfeng
Adler, Frederick R.
Chang, Jeffrey T.
Khan, Qamar J.
Bild, Andrea H.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5693
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Inhibition of Focal Adhesion Kinase Suppresses Adverse Features of Endocrine-Resistant Breast Cancer Cells and Improves Endocrine Response in ER plus , Endocrine-Sensitive Cells
    Hiscox, S.
    Barnfather, P.
    Hayes, E.
    Bramble, P.
    Christensen, J.
    Nicholson, R., I
    Barrett-Lee, P.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 689S - 689S
  • [32] Vascular endotelial growth factor and transforming growth factor-beta are enhanced in plasma of breast cancer patients resistant to endocrine therapy
    Zavadova, Eva
    Konopasek, Bohuslav
    Vocka, Michal
    Fucikova, Terezie
    Petruzelka, Lubos
    [J]. CANCER RESEARCH, 2012, 72
  • [33] Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
    Olukoya, Ayodeji O.
    Stires, Hillary
    Bahnassy, Shaymaa
    Persaud, Sonali
    Guerra, Yanira
    Ranjit, Suman
    Ma, Shihong
    Cruz, M. Idalia
    Benitez, Carlos
    Rozeboom, Aaron M.
    Ceuleers, Hannah
    Berry, Deborah L.
    Jacobsen, Britta M.
    Raj, Ganesh V.
    Riggins, Rebecca B.
    [J]. JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (10)
  • [34] ARID1A promotes endocrine resistance in ER plus breast cancer cells.
    Chabot, Catherine
    Basik, Mark
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [35] The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer
    Yuan, Jie
    Yang, Li
    Li, Zhi
    Zhang, Hua
    Wang, Qun
    Huang, Jun
    Wang, Bei
    Mohan, Chakrabhavi Dhananjaya
    Sethi, Gautam
    Wang, Geng
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [36] Chromatin remodeling agents enhance efficacy of 17b-estradiol therapy for endocrine-resistant ER plus breast cancer
    Johnson, A.
    Warren, A.
    Traphagen, N.
    Roberts, A.
    Barbara, K.
    Eugene, D.
    Kolling, F.
    Wilkins, O.
    Christensen, B.
    Miller, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 211 : S86 - S86
  • [37] Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC).
    Gumusay, Ozge
    Majure, Melanie Catherine
    Deal, Travis
    Renslo, Jonathan R.
    Wabl, Chiara A.
    Melisko, Michelle E.
    Chien, Amy Jo
    Goga, Andrei
    Moasser, Mark
    Park, John
    Hwang, Jimmy
    Rugo, Hope S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] FDXR drives primary and endocrine-resistant tumor cell growth in ER plus breast cancer via CPT1A-mediated fatty acid oxidation
    Yan, Chaojun
    Gao, Ronghui
    Gao, Chuan
    Hong, Kai
    Cheng, Meng
    Liu, Xiaojing
    Zhang, Qing
    Zhang, Jing
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [39] ESR1 gene fusions implicated in endocrine therapy resistance of ER plus breast cancer
    Shao, Jieya
    Zhang, Jin
    Crowder, Robert J.
    Goncalves, Rodrigo
    Phommaly, Chanpheng
    Perou, Charles M.
    Maher, Christopher A.
    Thompson, E. Aubrey
    Ellis, Matthew J.
    [J]. CANCER RESEARCH, 2015, 75
  • [40] Mutation signature of patients with ER plus metastatic breast cancer who received endocrine therapy.
    Ma, Fei
    Zhang, Yan
    Ouyang, Quchang
    Dai, Pingping
    Yi, Zongbi
    Cao, Weiguo
    Zhou, Yidong
    Zhu, Chenchen
    Guan, Yan-Fang
    Yang, Ling
    Yi, Xin
    Xia, Xuefeng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345